Regulation of cytosolic phospholipase A2alpha by hsp90 and a p54 kinase in okadaic acid-stimulated macrophages.
In resident mouse peritoneal macrophages, group IVA cytosolic phospholipase A(2) (cPLA(2)alpha) mediates arachidonic acid (AA) release and eicosanoid production in response to diverse agonists such as A23187, phorbol myristate acetate, zymosan, and the enterotoxin, okadaic acid (OA). cPLA(2)alpha is regulated by phosphorylation and by calcium that binds to the C2 domain and induces translocation from the cytosol to membranes. In contrast, OA activates cPLA(2)alpha-induced AA release and translocation to the Golgi in macrophages without an apparent increase in calcium. Inhibitors of heat shock protein 90 (hsp90), geldanamycin, and herbimycin blocked AA release in response to OA but not to A23187, PMA, or zymosan. OA, but not the other agonists, induced activation of a cytosolic serine/threonine 54-kDa kinase (p54), which phosphorylated cPLA(2)alpha in in-gel kinase assays and was associated with cPLA(2)alpha in immunoprecipitates. Activation of the p54 kinase was inhibited by geldanamycin. The kinase coimmunoprecipitated with hsp90 in unstimulated macrophages, and OA induced its loss from hsp90, concomitant with its association with cPLA(2)alpha. The results demonstrate a role for hsp90 in regulating cPLA(2)alpha-mediated AA release that involves association of a p54 kinase with cPLA(2)alpha upon OA stimulation.
Program in Cell Biology, National Jewish Medical and Research Center, 1400 Jackson St., Denver, CO 80206, USA.
Dawn E
DE
Tucker
Miguel A
MA
Gijón
Diane M
DM
Spencer
Zhi-Hua
ZH
Qiu
Michael H
MH
Gelb
Christina C
CC
Leslie
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D016227:Benzoquinones / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002273:Carcinogens / Q000494:pharmacology; D003600:Cytosol / Q000201:enzymology; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006056:Golgi Apparatus / Q000378:metabolism; D049452:Green Fluorescent Proteins / Q000378:metabolism; D054513:Group IV Phospholipases A2 / Q000378:metabolism*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D015151:Immunoblotting; D047468:Immunoprecipitation; D007476:Ionophores / Q000494:pharmacology; D047029:Lactams, Macrocyclic / Q000494:pharmacology; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D048057:Mitogen-Activated Protein Kinase 10 / Q000378:metabolism*; D041681:NIH 3T3 Cells; D019319:Okadaic Acid / Q000494:pharmacology*; D019606:Phosphoamino Acids / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D021381:Protein Transport; D017828:Rifabutin / Q000031:analogs & derivatives; D015398:Signal Transduction / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
D016227:Benzoquinones; D002273:Carcinogens; D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D007476:Ionophores; D047029:Lactams, Macrocyclic; D019606:Phosphoamino Acids; C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins; D019319:Okadaic Acid; D017828:Rifabutin; D016718:Arachidonic Acid; D000001:Calcimycin; C020754:herbimycin; D015054:Zymosan; D048057:Mitogen-Activated Protein Kinase 10; D054513:Group IV Phospholipases A2; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium; C001277:geldanamycin